Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer

Breast Cancer Research and Treatment

Volumn 131, Issue 1, 2012, Pages 33-40

  Strand, Carina ^a   Ahlin, Cecilia ^b   Bendahl, Pär Ola ^a   Fjällskog, Marie Louise ^c   Hedenfalk, Ingrid ^a   Malmström, Per ^a,d   Fernö, Mårten ^a  

^a LUND UNIVERSITY   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Cyclin A; ER status; Histological grade; Prognosis; Proliferation

Indexed keywords

CYCLIN A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; SYSTEMIC THERAPY; TISSUE MICROARRAY;

ADULT; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLIN A; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84856226232     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1386-5     Document Type: Article

References (31)

1. IR Bukholm G Bukholm JM Nesland 2001 Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas Int J Cancer 93 2 283 287 10.1002/ijc.1311 11410878 10.1002/ijc.1311 1:STN:280:DC%2BD3MzkslCitA%3D%3D (Pubitemid 32574286)
2. H Kuhling P Alm H Olsson M Ferno B Baldetorp R Parwaresch P Rudolph 2003 Expression of cyclins e, a, and b, and prognosis in lymph node-negative breast cancer J Pathol 199 4 424 431 10.1002/path.1322 12635132 10.1002/path.1322 (Pubitemid 36411218)
3. PJ van Diest E van der Wall JP Baak 2004 Prognostic value of proliferation in invasive breast cancer: a review J Clin Pathol 57 7 675 681 10.1136/jcp.2003.010777 15220356 10.1136/jcp.2003.010777 57/7/675 [pii] (Pubitemid 38901478)
4. E Baldini A Camerini A Sgambato T Prochilo A Capodanno F Pasqualetti C Orlandini L Resta G Bevilacqua P Collecchi 2006 Cyclin a and e2f1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients Anticancer Res 26 6B 4415 4421 17201163 1:CAS:528: DC%2BD2sXpslCqtg%3D%3D (Pubitemid 46031516)
5. E de Azambuja F Cardoso G de Castro Jr. M Colozza MS Mano V Durbecq C Sotiriou D Larsimont MJ Piccart-Gebhart M Paesmans 2007 Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients Br J Cancer 96 10 1504 1513 6603756[pii] 17453008 10.1038/sj.bjc.6603756 10.1038/sj.bjc.6603756 (Pubitemid 46762956)
6. R Stuart-Harris C Caldas SE Pinder P Pharoah 2008 Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32, 825 patients Breast 17 4 323 334 S0960-9776(08)00059-3[pii] 18455396 10.1016/j.breast.2008.02.002 1:STN:280:DC%2BD1crgs1Kruw%3D%3D 10.1016/j.breast.2008.02.002
7. JP Baak E Gudlaugsson I Skaland LH Guo J Klos TH Lende H Soiland EA Janssen A Zur Hausen 2009 Proliferation is the strongest prognosticator in node-negative breast cancer: Significance, error sources, alternatives and comparison with molecular prognostic markers Breast Cancer Res Treat 115 2 241 254 10.1007/s10549-008-0126-y 18665447 10.1007/s10549-008-0126-y 1:CAS:528:DC%2BD1MXmsVCqu7c%3D
8. A Goldhirsch JN Ingle RD Gelber AS Coates B Thurlimann HJ Senn 2009 Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 8 1319 1329 mdp322[pii] 19535820 10.1093/annonc/mdp322 1:STN:280: DC%2BD1Mrjtlyhug%3D%3D 10.1093/annonc/mdp322
9. R Michalides H van Tinteren A Balkenende JB Vermorken J Benraadt J Huldij P van Diest 2002 Cyclin a is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment Br J Cancer 86 3 402 408 10.1038/sj.bjc.6600072 11875707 10.1038/sj.bjc.6600072 1:CAS:528: DC%2BD38XisFOls78%3D (Pubitemid 34185125)
10. P Poikonen J Sjostrom RM Amini K Villman J Ahlgren C Blomqvist 2005 Cyclin a as a marker for prognosis and chemotherapy response in advanced breast cancer Br J Cancer 93 5 515 519 6602735[pii] 16091759 10.1038/sj.bjc.6602735 1:CAS:528:DC%2BD2MXpsFalur8%3D 10.1038/sj.bjc.6602735 (Pubitemid 43079993)
11. C Ahlin W Zhou M Holmqvist L Holmberg C Nilsson K Jirstrom C Blomqvist RM Amini ML Fjallskog 2009 Cyclin a is a proliferative marker with good prognostic value in node-negative breast cancer Cancer Epidemiol Biomarkers Prev 18 9 2501 2506 1055-9965.EPI-09-0169[pii] 19706846 10.1158/1055-9965.EPI-09-0169 1:CAS:528:DC%2BD1MXhtFWltLfN 10.1158/1055-9965.EPI-09-0169
12. P Rudolph H Kuhling P Alm M Ferno B Baldetorp H Olsson R Parwaresch 2003 Differential prognostic impact of the cyclins e and b in premenopausal and postmenopausal women with lymph node-negative breast cancer Int J Cancer 105 5 674 680 10.1002/ijc.11132 12740917 10.1002/ijc.11132 1:CAS:528: DC%2BD3sXkvFSgs7g%3D (Pubitemid 36687736)
13. R Konigsberg O Rogelsperger W Jager T Thalhammer M Klimpfinger M De Santis M Hudec C Dittrich 2008 Cell cycle dysregulation influences survival in high risk breast cancer patients Cancer Invest 26 7 734 740 795398532[pii] 18665474 10.1080/07357900801944864 10.1080/07357900801944864
14. C Sotiriou P Wirapati S Loi A Harris S Fox J Smeds H Nordgren P Farmer V Praz B Haibe-Kains C Desmedt D Larsimont F Cardoso H Peterse D Nuyten M Buyse MJ Van de Vijver J Bergh M Piccart M Delorenzi 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 98 4 262 272 16478745 10.1093/jnci/djj052 1:CAS:528:DC%2BD28Xhs1Skt74%3D (Pubitemid 43264710)
15. AV Ivshina J George O Senko B Mow TC Putti J Smeds T Lindahl Y Pawitan P Hall H Nordgren JE Wong ET Liu J Bergh VA Kuznetsov LD Miller 2006 Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer Cancer Res 66 21 10292 10301 66/21/10292[pii] 17079448 10.1158/0008-5472.CAN-05-4414 1:CAS:528:DC%2BD28XhtFGjsrjM 10.1158/0008-5472. CAN-05-4414 (Pubitemid 44799747)
16. AE Teschendorff A Miremadi SE Pinder IO Ellis C Caldas 2007 An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer Genome Biol 8 8 R157 gb-2007-8-8-r157[pii] 17683518 10.1186/gb-2007-8-8-r157 10.1186/gb-2007-8-8-r157 (Pubitemid 351891480)
17. C Desmedt B Haibe-Kains P Wirapati M Buyse D Larsimont G Bontempi M Delorenzi M Piccart C Sotiriou 2008 Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes Clin Cancer Res 14 16 5158 5165 14/16/5158[pii] 18698033 10.1158/1078-0432.CCR-07-4756 1:CAS:528:DC%2BD1cXpslKgur4%3D 10.1158/1078-0432.CCR-07-4756
18. M Klintman PO Bendahl D Grabau K Lovgren P Malmstrom M Ferno 2010 The prognostic value of ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer Mod Pathol 23 2 251 259 modpathol2009167[pii] 19935641 10.1038/modpathol.2009. 167 1:CAS:528:DC%2BC3cXhsVyjtbw%3D 10.1038/modpathol.2009.167
19. MA Aleskandarany EA Rakha RD Macmillan DG Powe IO Ellis AR Green 2010 Mib1/ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups Breast Cancer Res Treat 10.1007/s10549-010-1028-3
20. P Malmstrom PO Bendahl P Boiesen N Brunner I Idvall M Ferno 2001 S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham prognostic index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer J Clin Oncol 19 7 2010 2019 11283134 1:CAS:528:DC%2BD3MXjtVyhu7w%3D (Pubitemid 32702545)
21. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 5 403 410 1757079 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D
22. C Ahlin K Aaltonen RM Amini H Nevanlinna ML Fjallskog C Blomqvist 2007 Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51 4 491 498 HIS2798[pii] 17711446 10.1111/j.1365-2559.2007.02798.x 1:STN:280:DC%2BD2srmtFWhug%3D%3D 10.1111/j.1365-2559.2007.02798.x (Pubitemid 47437828)
23. G Jonsson J Staaf J Vallon-Christersson M Ringner K Holm C Hegardt H Gunnarsson R Fagerholm C Strand BA Agnarsson O Kilpivaara L Luts P Heikkila K Aittomaki C Blomqvist N Loman P Malmstrom H Olsson OT Johannsson A Arason H Nevanlinna RB Barkardottir A Borg 2010 Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics Breast Cancer Res 12 3 R42 bcr2596[pii] 20576095 10.1186/bcr2596 10.1186/bcr2596
24. DA Schoenfeld 1983 Sample-size formula for the proportional-hazards regression model Biometrics 39 2 499 503 6354290 10.2307/2531021 1:STN:280:DyaL2c%2FisVyqtQ%3D%3D (Pubitemid 14267522)
25. Royston P, Sauerbrei W (2008) Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for continuous variables. John Wiley & Sons Ltd, Chichester
26. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 Reporting recommendations for tumor marker prognostic studies (remark) Breast Cancer Res Treat 100 2 229 235 10.1007/s10549-006-9242-8 16932852 10.1007/s10549-006-9242-8 (Pubitemid 44631925)
27. M Dowsett A Goldhirsch DF Hayes HJ Senn W Wood G Viale 2007 International web-based consultation on priorities for translational breast cancer research Breast Cancer Res 9 6 R81 bcr1798[pii] 18034879 10.1186/bcr1798 10.1186/bcr1798
28. P Eden C Ritz C Rose M Ferno C Peterson 2004 "Good old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers Eur J Cancer 40 12 1837 1841 10.1016/j.ejca.2004.02. 025 15288284 10.1016/j.ejca.2004.02.025 1:CAS:528:DC%2BD2cXmt1OitLo%3D S0959804904002138 [pii] (Pubitemid 39036757)
29. J Cuzick M Dowsett C Wale J Salter E Quinn L Zabaglo A Howell A Buzdar J Forbes 2009 Prognostic value of a combined ER, PgR, ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score: results from transATAC Cancer Res 69 Suppl 24 503S 503S
30. JS Meyer C Alvarez C Milikowski N Olson I Russo J Russo A Glass BA Zehnbauer K Lister R Parwaresch 2005 Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index Mod Pathol 18 8 1067 1078 3800388[pii] 15920556 10.1038/modpathol.3800388 10.1038/modpathol.3800388 [doi] (Pubitemid 41224497)
31. K Aaltonen C Ahlin RM Amini L Salonen ML Fjallskog P Heikkila H Nevanlinna C Blomqvist 2006 Reliability of cyclin a assessment on tissue microarrays in breast cancer compared to conventional histological slides Br J Cancer 94 11 1697 1702 6603147[pii] 16670718 1:CAS:528:DC%2BD28XltVOmtbw%3D 10.1038/sj.bjc.6603147 (Pubitemid 43924935)